KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.
KAHR’s drug development pipeline is built around the 'Signal Converter Proteins' (SCP) technology, the outgrowth of research carried out over a decade at the University of Pennsylvania and the Hadassah Medical Center. The results of these research efforts have been published in multiple scientific publications.
The enhanced architecture of SCP molecules creates fusion-proteins with two functional ends. Both ends act together as a team – one end blocks clinically undesirable inter-cellular signals while the other converts these signals to clinically desirable ones.
This structure allows the chimeric (fused) SCP molecule to possess two biologically active ends, facilitating a unique mode-of-action in which two reinforcing signals drive increased activity, specificity and therapeutic benefits that cannot be achieved by simply administering the SCP protein elements as separate units.
SCP molecules are especially effective in targeting complex biological processes in the immune system that rely on intricate inter-cellular communications, while in cancer they exploit the abnormal receptor expression of cancer cells to selectively cause death by apoptosis of these malignant cells. Both lead products are potential drugs for the treatment of multiple cancers and autoimmune diseases. KAHR plans to initially assess both KAHR-101 and KAHR-102 in clinical trials for the treatment of cancer.
KAHR-Medical promises to significantly extend the repertoire of protein pharmaceuticals available for cancer and autoimmune patients, and is currently developing two SCP drug candidates, KAHR-101 and KAHR-102, towards clinical trials.